PROCEPT BioRobotics Achieves Strong Third Quarter Results
PROCEPT BioRobotics (NASDAQ: PRCT) has marked a significant milestone with its recent third-quarter earnings, surpassing expectations and showcasing impressive growth in various key areas. Traders and investors are closely watching the company following the release of these results that have stirred optimism in the market.
Quarterly Earnings Overview
In its latest financial report, PROCEPT revealed an earnings per share (EPS) loss of $(0.40), notably improved from $(0.51) during the same quarter last year. This figure surpassed the anticipated consensus loss of $(0.49), indicating a positive trend that has caught the attention of analysts.
Sales Performance Surges
The surgical robotics provider reported quarterly revenues totaling $58.4 million, reflecting a robust year-over-year growth of 66.3%. Analysts had projected a lower revenue of approximately $53.18 million, further emphasizing the company’s strong sales performance.
Driving Factors Behind Revenue Growth
This substantial increase was primarily fueled by a rise in system sales and higher average selling prices. Additionally, revenue from handpieces and other consumables also saw a significant uptick. Specifically, sales of U.S. handpieces and consumables reached $29.6 million in the third quarter of 2024, marking a remarkable 74% increase from the previous year.
Insights from Analysts
In particular, William Blair noted that the update from PROCEPT BioRobotics is encouraging. The fact that management addressed potential procedural disruptions due to staff training on a new system, specifically the Hydros system, shows transparency and foresight. Despite these changes, U.S. system revenue for Q3 2024 climbed by 46%, totaling $19.6 million.
Expansion of Robotic Systems
As of the end of September, the total installed base of robotic systems in the United States has reached 445 systems. This expansion illustrates the growing adoption of PROCEPT’s technology within the healthcare sector.
Gross Margin Improvements
The company's gross margin also showed considerable improvement, rising to 63.2% compared to 53.8% in the previous year. Much of this increase can be attributed to enhanced overhead absorption and elevated average selling prices of U.S. robotic systems.
Future Revenue Guidance
Looking ahead, PROCEPT BioRobotics is optimistic about its financial trajectory, forecasting 2024 revenue between $222.5 million and $223 million. This represents an upward adjustment from prior guidance of $217 million, aligning closely with the consensus expectation of $217.06 million.
Adjusted EBITDA Projections
The company anticipates an adjusted EBITDA loss of ($60.0) million for the full-year 2024, an improvement from earlier guidance expecting a loss of ($67.5) million. This adjustment reflects the company’s commitment to improving its operational efficiency and profitability.
Market Potential and Analyst Optimism
William Blair remains upbeat about PROCEPT’s prospects, asserting that there is little to critique in the third-quarter results. The ongoing strong demand for Aquablation—a minimally invasive robotic procedure for prostate treatment—supports this view. With penetration into the U.S. market still projected to be only 10% by the end of 2024, accompanied by a strong estimated utilization growth of 7%, there is substantial room for expansion. PROCEPT’s upcoming launch of the Hydros system and its efforts to enhance profitability further solidify this optimism.
Stock Market Response
Following these announcements, shares of PRCT have climbed by 28.50%, with stock trading at $88.36 during the latest market check. This surge underscores the positive reception to the company’s financial results and future outlook.
Frequently Asked Questions
What were PROCEPT BioRobotics' earnings for Q3 2024?
The company reported an EPS loss of $(0.40), an improvement from $(0.51) the previous year.
How much revenue did PROCEPT generate in Q3 2024?
PROCEPT reported third-quarter sales of $58.4 million, a 66.3% increase year-over-year.
What are the future projections for PROCEPT BioRobotics?
For 2024, the company projects revenue between $222.5 million and $223 million, a rise from earlier estimates.
What is driving the revenue growth at PROCEPT?
The increase is driven by higher system sales, increased average selling prices, and substantial sales in consumables.
How have analysts reacted to PROCEPT's third-quarter performance?
Analysts, including William Blair, have expressed optimism regarding the company's prospects, citing strong underlying demand for its products.
